Dimerix gains as FDA approves commercial brand name for kidney disease

Dimerix

25/09/2023 04:20

** Shares of Australian clinical-stage biopharmaceutical
company Dimerix  DXB.AX  rise as much as 9.7% to A$0.068,
marking their biggest intraday pct gain since Aug. 2
    ** DXB at its highest level since Sept. 21    
    ** Co receives conditional approval from U.S. Food and Drug
Administration for brand name Qytovra 
    ** Adds approval for phase 3 clinical drug candidate in
focal segmental glomerulosclerosis, a kidney disease
    ** Stock down 56.3% YTD, as of last close, vs a 0.43%
increase in benchmark S&P/ASX 200 index  .AXJO 

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com;))